ebola-virus

Documents about ebola-virus

• Experimental Vaccine for Prevention of Ebola Virus Infection#414372ClinicalTrials.gov
• Whose fears count? Legitimacy, trust and viral outbreak responses after COVID-19#393156PLOS
• REVIVE (Response to the Ebola Virus Vaccine)#353345ClinicalTrials.gov
• Fear, stigma and Uncertainty: The short and long-term effects of Ebola on survivors, affected families, and community in Bundibugyo, Western Uganda#672183PLOS
• Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)#18697ClinicalTrials.gov
• R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease#917776ClinicalTrials.gov
• EBOla Post-Exposure Prophylaxis#245567ClinicalTrials.gov
• Ebola and Marburg Virus Vaccines#901254ClinicalTrials.gov
• Ebola virus and Sudan virus infection in humans: a comparison to inform vaccine research and development#642677Europe PMC
• Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response#148782ClinicalTrials.gov
• A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV#261336ClinicalTrials.gov
• A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants#901804ClinicalTrials.gov
• Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon#287392ClinicalTrials.gov
• Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up#872629ClinicalTrials.gov
• Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)#913398ClinicalTrials.gov
• Efficacy of Favipiravir Against Ebola (JIKI)#217068ClinicalTrials.gov
• Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)#261362ClinicalTrials.gov
• Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda#968427ClinicalTrials.gov
• Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC#459971ClinicalTrials.gov
• Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment#860756ClinicalTrials.gov
• EBOVAC-Salone Extension#180202ClinicalTrials.gov
• Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)#146254ClinicalTrials.gov
• WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks,...#237670World Health Organization
• A smart phone based expert system for airport screening of infectious diseases : test case with the Ebola virus symptoms#938651SU+ Digital Repository
• A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.#424244ClinicalTrials.gov
• The mental health professional at the feet of the Ebola virus: individual treatment and global mental challenges#250234HAL (France)
• Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)#832388ClinicalTrials.gov
• Ebola at a critical juncture: preparedness must outpace transmission#349389WHO IRIS
• Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)#152516ClinicalTrials.gov
• A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.#882001ClinicalTrials.gov
• Ebola virus disease: A persistent challenge in global health security.#323262NCBI PubMed Central
• Hippo signalling as a nexus in host–virus interactions#275950PLOS
• The Ebola Virus and West Africa: Medical and Sociocultural Aspects#497371ScholarSpace
• Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults#346967ClinicalTrials.gov
• The Diagnostic testing for Ebola disease and Marburg virus disease: interim guidance, 9 July 2026#369343World Health Organization
• WHO emergency guidance on the use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks,...#632341World Health Organization
• Ebola Virus Disease Democratic Republic of Congo: External Situation Report 22#139616WHO IRIS
• Ebola virus disease in the Democratic Republic of the Congo, 1976-2014: Figures and Data#304852LSHTM Data Compass
• Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults#390969ClinicalTrials.gov
• A simple mathematical model for Ebola in Africa#990198University of Pretoria Repository
• Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health#152499ClinicalTrials.gov
• A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants#174973ClinicalTrials.gov
• Shifting patterns of importation risk of Bundibugyo Ebola virus disease to Europe under outbreak expansion scenarios#337054bioRxiv / medRxiv
• Estimation of the size of the Ebola outbreak caused by Bundibugyo virus in the Democratic Republic of the Congo#928220PubMed Central
• Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers#152476ClinicalTrials.gov
• Infection prevention and control considerations for routine immunization activities during the Bundibugyo virus disease outbreak: interim guidance, 21 August 2026#484366WHO IRIS
• إرشادات منظمة الصحة العالمية بشأن فعاليات التجمعات الحاشدة التي يحضرها أفراد قادمون من مناطق وُثِّق رصد فيروس بونديبوغيو فيها، أيار/ مايو 2026#349393WHO IRIS
• Cost-effectiveness of geographically targeted versus ring vaccination campaigns in response to an outbreak of Ebola Virus Disease caused by Orthoebolavirus zairense#474703bioRxiv / medRxiv
• Weekly External Situation Report 18, Data as of 13 September 2026 - Democratic Republic of the Congo and Uganda#928986WHO IRIS
• VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults#668851ClinicalTrials.gov